Skip to main content

Advertisement

Log in

The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Epidemiological studies have assessed the association between Fc gamma receptor IIIA (FCGR3A) 158 V/F and the response to rituximab-based therapy in patients with non-Hodgkin lymphoma (NHL), but the findings have been inconsistent. We performed this meta-analysis to obtain a better assessment of this relationship. Electronic database searches were conducted for relevant studies. A pooled odds ratio (OR) with a 95 % confidence interval (95 % CI) was used to assess the strength of the association. Analyses of the subgroup and publication bias were conducted. A total of 10 studies involving 1050 patients were analyzed. In all the genetic models, no clear relationship was found between the FCGR3A 158 V/F polymorphism and the response to rituximab-based therapy in NHL patients. When categorized by ethnicity, Asian individuals with the FCGR3A 158 V/V allele (OR = 4.37; 95 % CI = 1.07–17.73; P = 0.039) or the non-F/(FV + VV) (OR = 2.50; 95 % CI = 1.04–5.98; P = 0.040) allele have a significantly higher complete response rate (CR) compared to FF individuals. No obvious heterogeneities were observed. In addition, no statistical evidence for a publication bias was found. Our study suggested that the FCGR3A 158 V/F polymorphism can predict the treatment response to rituximab-based chemotherapy in NHL patients, especially for Asian individuals.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’ Etude des Lymphomes de l’Adulte. J Clin Oncol 23(18):4117–4126

    Article  CAS  PubMed  Google Scholar 

  2. Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M, MabThera International Trial Group (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7(5):379–391

    Article  CAS  PubMed  Google Scholar 

  3. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6(4):443–446

    Article  CAS  PubMed  Google Scholar 

  4. Ravetch JV, Bolland S (2001) IgG Fc receptors. Annu Rev Immunol 19:275–290, Review

    Article  CAS  PubMed  Google Scholar 

  5. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M (1997) Fc gammaRIIIa-158 V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 90(3):1109–1114

    CAS  PubMed  Google Scholar 

  6. Liu F, Ding H, Jin X, Ding N, Deng L, He Y, Zhu J, Song Y (2014) FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma. DNA Cell Biol 33(9):616–623. doi:10.1089/dna.2013.2333

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Váróczy L, Zilahi E, Gyetvai A, Kajtár B, Gergely L, Sipka S, Illés A (2012) Fc-gamma-receptor IIIa polymorphism and gene expression profile do not predict the prognosis in diffuse large B-cell lymphoma treated with R-CHOP protocol. Pathol Oncol Res 18(1):43–48. doi:10.1007/s12253-011-9414-7

    Article  PubMed  Google Scholar 

  8. Ghesquières H, Cartron G, Seymour JF, Delfau-Larue MH, Offner F, Soubeyran P, Perrot A, Brice P, Bouabdallah R, Sonet A, Dupuis J, Casasnovas O, Catalano JV, Delmer A, Jardin F, Verney A, Dartigues P, Salles G (2012) Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. Blood 120(13):2650–2657

    Article  PubMed  Google Scholar 

  9. Cornec D, Tempescul A, Querellou S, Hutin P, Pers JO, Jamin C, Bendaoud B, Berthou C, Renaudineau Y, Youinou P (2012) Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy. Ann Hematol 91(5):715–721. doi:10.1007/s00277-011-1369-y

    Article  CAS  PubMed  Google Scholar 

  10. Fabisiewicz A, Paszkiewicz-Kozik E, Osowiecki M, Walewski J, Siedlecki JA (2011) FcγRIIA and FcγRIIIA polymorphisms do not influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 52(8):1604–1606. doi:10.3109/10428194.2011.574760

    Article  CAS  PubMed  Google Scholar 

  11. Zhang W, Wang X, Li J, Duan MH, Zhou DB (2010) Fcgamma receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese diffuse large B-cell lymphoma. Chin Med J (Engl) 123(2):198–202

    CAS  Google Scholar 

  12. Mitroviç Z, Aurer I, Radman I, Ajdukoviç R, Sertiç J, Labar B (2007) FCgammaR IIIA and FCgammaR IIA polymorphisms are not associated with response to rituximaband CHOP in patients with diffuse large B-cell lymphoma. Haematologica 92(7):998–999

    Article  PubMed  Google Scholar 

  13. Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, Do YR, Shin HJ, Kim MK, Hyun MS, Sohn SK (2006) FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 108(8):2720–2725

    Article  CAS  PubMed  Google Scholar 

  14. Galimberti S, Palumbo GA, Caracciolo F, Benedetti E, Pelosini M, Brizzi S, Ciabatti E, Fazzi R, Stelitano C, Quintana G, Conte E, Tibullo D, Di Raimondo F, Petrini M (2007) The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaR IIIa and FCgammaR IIa polymorphisms. J Chemother 19(3):315–321

    Article  CAS  PubMed  Google Scholar 

  15. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaR IIIa gene. Blood 99(3):754–758

    Article  CAS  PubMed  Google Scholar 

  16. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207–214

    Article  CAS  PubMed  Google Scholar 

  17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216

    Article  CAS  PubMed  Google Scholar 

  18. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Nat Cancer Inst 22(4):719–748

    CAS  PubMed  Google Scholar 

  19. Burchard PR, Malhotra S, Kaur P, Tsongalis GJ (2013) Detection of the FCGR3a polymorphism using a real-time polymerase chain reaction assay. Cancer Genet 206(4):130–134. doi:10.1016/j.cancergen.2013.03.002

    Article  CAS  PubMed  Google Scholar 

  20. Mishima Y, Terui Y, Mishima Y, Kuniyoshi R, Matsusaka S, Mikuniya M, Kojima K, Hatake K (2012) High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcγRIIIa polymorphism. Int Immunol 24(8):477–483. doi:10.1093/intimm/dxs048

    Article  CAS  PubMed  Google Scholar 

  21. Veeramani S, Wang SY, Dahle C, Blackwell S, Jacobus L, Knutson T, Button A, Link BK, Weiner GJ (2011) Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood 118(12):3347–3349. doi:10.1182/blood-2011-05-351411

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Ternant D, Cartron G, Hénin E, Tod M, Girard P, Paintaud G (2012) Model-based design of rituximab dosage optimization in follicular non-Hodgkin’s lymphoma. Br J Clin Pharmacol 73(4):597–605. doi:10.1111/j.1365-2125.2011.04125.x

    Article  CAS  PubMed  Google Scholar 

  23. Prochazka V, Papajik T, Gazdova J, Divoka M, Rozmanova S, Faber E, Raida L, Kucerova L, Langova K, Jarosova M, Indrak K (2011) FcγRIIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy. Neoplasma 58(3):263–270

    Article  CAS  PubMed  Google Scholar 

  24. Ternant D, Cartron G, Hénin E, Tod M, Paintaud G, Girard P (2009) Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin’s lymphoma. Br J Clin Pharmacol 68(4):561–573. doi:10.1111/j.1365-2125.2009.03494.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Weng WK, Levy R (2009) Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. Leuk Lymphoma 50(5):723–727. doi:10.1080/10428190902829441

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Lejeune J, Thibault G, Ternant D, Cartron G, Watier H, Ohresser M (2008) Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies. J Clin Oncol 26(33):5489–5491. doi:10.1200/JCO.2008.19.4118

    Article  PubMed  Google Scholar 

  27. Hatjiharissi E, Hansen M, Santos DD, Xu L, Leleu X, Dimmock EW, Ho AW, Hunter ZR, Branagan AR, Patterson CJ, Kortsaris A, Verselis S, Fox E, Treon SP (2007) Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Clin Lymphoma Myeloma 7(4):286–290

    Article  CAS  PubMed  Google Scholar 

  28. Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, Modica M, Cao Y, Manning RJ, Leleu X, Dimmock EA, Kortsaris A, Mitsiades C, Anderson KC, Fox EA, Treon SP (2007) Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood 110(7):2561–2564

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Dall’Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G (2004) Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 64(13):4664–4669

    Article  PubMed  Google Scholar 

  30. Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21(21):3940–3947

    Article  CAS  PubMed  Google Scholar 

  31. Carlotti E, Palumbo GA, Oldani E, Tibullo D, Salmoiraghi S, Rossi A, Golay J, Pulsoni A, Foà R, Rambaldi A (2007) FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin’s lymphoma patients treated with sequential CHOP and rituximab. Haematologica 92(8):1127–1130

    Article  CAS  PubMed  Google Scholar 

  32. Ahlgrimm M, Pfreundschuh M, Kreuz M, Regitz E, Preuss KD, Bittenbring J (2011) The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab. Blood 118(17):4657–4662. doi:10.1182/blood-2011-04-346411

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Persky DO, Dornan D, Goldman BH, Braziel RM, Fisher RI, Leblanc M, Maloney DG, Press OW, Miller TP, Rimsza LM (2012) Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica 97(6):937–942. doi:10.3324/haematol.2011.050419

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Weng WK, Negrin RS, Lavori P, Horning SJ (2010) Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin’s lymphoma. J Clin Oncol 28(2):279–284. doi:10.1200/JCO.2009.25.0274

    Article  CAS  PubMed  Google Scholar 

  35. Keane C, Nourse JP, Crooks P, Nguyen-Van D, Mutsando H, Mollee P, Lea RA, Gandhi MK (2012) Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma. Intern Med J 42(10):1113–1119. doi:10.1111/j.1445-5994.2011.02587.x

    Article  CAS  PubMed  Google Scholar 

  36. Li SC, Chen YC, Evens AM, Lee CC, Liao HF, Yu CC, Tung YT, Su YC (2010) Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism. Am J Hematol 85(10):810–812. doi:10.1002/ajh.21818

    Article  PubMed  Google Scholar 

  37. Sarsour K, Greenberg J, Johnston JA, Nelson DR, O’Brien LA, Oddoux C, Ostrer H, Pearlman A, Reed G (2013) The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-α antagonist therapies. Clin Exp Rheumatol 31(2):189–194

    PubMed  Google Scholar 

  38. Cartron G (2009) FCGR3A polymorphism story: a new piece of the puzzle. Leuk Lymphoma 50(9):1401–1402. doi:10.1080/10428190903161109

    Article  CAS  PubMed  Google Scholar 

  39. Ternant D, Paintaud G (2005) Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther 5(Suppl 1):S37–S47, Review

    Article  CAS  PubMed  Google Scholar 

  40. Zhuang Y, Xu W, Shen Y, Li J (2010) Fcγ receptor polymorphisms and clinical efficacy of rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 10(5):347–352. doi:10.3816/CLML.2010.n.067

    Article  CAS  PubMed  Google Scholar 

  41. Treon SP (2010) Fcγ receptor predictive genomic testing and the treatment of indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 10(5):321–322. doi:10.3816/CLML.2010.n.063

    Article  PubMed  Google Scholar 

  42. Zhuang Y, Qiao C, Yang G, Shen Y, Qian X, Yang L, Xu W, Li J (2014) FcγRIIIa polymorphisms and efficacy of Rituximab combined chemotherapy for diffuse large B-cell lymphoma in Chinese patients. Zhonghua Xue Ye Xue Za Zhi 35(9):816–821. doi:10.3760/cma.j.issn.0253-2727.2014.09.007

    CAS  PubMed  Google Scholar 

  43. Zhang W, Wang X, Duan MH, Li J, Zhou DB (2009) Efficacy of rituximab therapy on diffuse large B-cell lymphoma with different Fcgamma RIIIA gene polymorphisms: a prospective study. Zhonghua Yi Xue Za Zhi 89(6):400–402

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from the Fund of the Outstanding Youth foundation of Heilongjiang Province of China (Grant No. JC201215) and the Science and Technology Research Project of Chinese Ministry of Education (Grant No.213010A), Heilongjiang Province Education Department project (Grant No. 2012CJHB007).

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Yan Jin or Mei Dong.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, D., Tian, Y., Sun, D. et al. The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis. Ann Hematol 95, 1483–1490 (2016). https://doi.org/10.1007/s00277-016-2723-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-016-2723-x

Keywords

Navigation